Neos Therapeutics to Present at the Wells Fargo Securities Healthcare Conference on September 8, 2016

DALLAS and FORT WORTH, Texas, Aug. 31, 2016 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Vipin Garg, PhD, President and CEO, will present at the Wells Fargo Securities 2016 Healthcare Conference on Thursday, September 8, 2016 at 9:55 a.m. ET in Boston, MA. Dr. Garg will provide a corporate update and discuss the Company’s key milestones and events, including the launch of Adzenys XR-ODT™, the first and only extended-release, orally disintegrating tablet for the treatment of ADHD and the Company’s first branded product commercially available in the United States.

A live webcast of the presentation will be available on the investor section of the company’s website, http://investors.neostx.com/. The webcast will be archived on the website following the presentation.

About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platforms. Adzenys XR-ODT is the first approved product using the Company’s XR-ODT technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®¹, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.

¹Tussionex® is a registered trademark of the UCB Group of Companies.

CONTACT:

Richard I. Eisenstadt, Chief Financial Officer
Neos Therapeutics
(972) 408‐1389
[email protected]